Success Stories

December 2019 Question of the Month

How likely are payers to focus on formulary placement or exclusion for unapproved products (i.e. medical foods)?

Somewhat likely for exclusion purposes only: 72%

No change in focus from today: 14%

Unlikely: 14%

Highly likely: 0%

November 2019 Question of the Month

The new Fair and Accurate Medicaid Pricing Act excludes Authorized Generics (AG) from AMP calculations for brand manufacturers, likely increasing their AMP prices and subsequent rebates. How will this change effect brand manufacturers decision to launch an AG or not?

Brand manufacturer will reconsider when to launch the AG and only launch after an ANDA is approved: 100%

Brand manufacturer will launch the AG before the ANDA is introduced in the market: 0%

The Act will not impact brand manufacturers’ decisions to launch AGs: 0%

Brand manufacturers will not launch AG’s any longer: 0%